Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

Clasificación en acciones #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Precio por acción
$6.89
Capitalización bursátil
$43.94B
Cambio (1 día)
-2.91%
Cambio (1 año)
-24.78%
País
CN
Comercio Jiangsu Hengrui Medicine Co., Ltd. (600276)

Categoría

Healthcare
Ratio P/B de Jiangsu Hengrui Medicine Co., Ltd. (600276)
Ratio P/B al October 2026 TTM: 4.71
Según los informes financieros más recientes y el precio de las acciones de Jiangsu Hengrui Medicine Co., Ltd., el ratio P/B actual (TTM) es 4.71. Al final de 2024, el ratio P/B era 6.39.
Historial del ratio P/B de Jiangsu Hengrui Medicine Co., Ltd. desde 2001 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) 4.71 -25.48%
2025 6.32 -1.09%
2024 6.39 -9.65%
2023 7.07 9.04%
2022 6.49 -29.84%
2021 9.24 -52.24%
2020 19.35 24.50%
2019 15.55 57.24%
2018 9.89 -5.23%
2017 10.43 45.32%
2016 7.18 -10.85%
2015 8.05 63.76%
2014 4.92 -13.09%
2013 5.66 13.80%
2012 4.97 -8.81%
2011 5.45 -40.25%
2010 9.12 4.84%
2009 8.70 25.59%
2008 6.93 -35.14%
2007 10.68 89.97%
2006 5.62 451.70%
2005 1.02 5.76%
2004 0.96 -9.87%
2003 1.07 -10.67%
2002 1.20 -6.19%
2001 1.28 0.00%
Ratio P/B de empresas similares o competidoras